CKD-516 + durvalumab

CKD-516 + durvalumab is an investigational combination therapy for refractory solid tumors and other advanced cancers. CKD-516 (also known as valecobulin) is a small molecule vascular disrupting agent that targets established tumor vasculature by inhibiting tubulin polymerization, leading to rapid destruction of tumor blood vessels and subsequent tumor necrosis. Durvalumab is a human monoclonal antibody immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune responses by blocking the interaction between PD-L1 and its receptors on T cells. The combination aims to synergistically disrupt tumor vasculature while promoting immune-mediated cancer cell killing. Clinical trials are ongoing in various solid tumors including cholangiocarcinoma, colorectal cancer, esophageal cancer, gastric cancer, and other gastrointestinal malignancies[1][3][8].

Brand names

Imfinzi

Other names

valecobulinMEDI4736MEDI-4736MEDI 4736